Neurocrine Biosciences (NBIX) Tops Q3 EPS by 28c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 11/3/2026
- Nasdaq ends higher as AI heavyweights rebound ahead of midterm results
- Apple shares slip amid guidance for tightening margins, slowing services growth
- Rising shorts cool U.S. large-cap positioning, cutting liquidation risk: Citi
- Apple's 'unprecedented' memory warning adds fuel to wobbly Micron, SK hynix trade
- Palantir raises 2026 revenue outlook after quarterly revenue nearly doubles on AI
Tweet
Share
E-mail
Get Alerts NBIX Hot Sheet
Price: $164.85 +13.42%
Financial Fact:
Total operating expenses: 38.44M
Today's EPS Names:
FUSE, INM, TRI, More
Financial Fact:
Total operating expenses: 38.44M
Today's EPS Names:
FUSE, INM, TRI, More
Join SI Premium – FREE
Neurocrine Biosciences (NASDAQ: NBIX) reported Q3 EPS of $1.08, $0.28 better than the analyst estimate of $0.80. Revenue for the quarter came in at $387.9 million versus the consensus estimate of $376.55 million.
For earnings history and earnings-related data on Neurocrine Biosciences (NBIX) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Ultragenyx Pharma (RARE) Misses Q3 EPS by 6c; Offers Guidance
- LATAM Airlines (LTM) Misses Q3 EPS by 135c
- Ovintiv Inc. (OVV) Tops Q3 EPS by 3c
Create E-mail Alert Related Categories
EarningsRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
